Af­ter pre­sid­ing over stormy years, John McHutchi­son picks his 's­trate­gic part­ner' to run As­sem­bly Bio

Through­out the string of neg­a­tive news com­ing out of As­sem­bly Bio, CEO John McHutchi­son held on to the hope that his team of an­tivi­ral ex­perts would de­liv­er a func­tion­al cure for he­pati­tis B. Even as the biotech scrapped its lead drug, he point­ed to the promise of next-gen­er­a­tion pro­grams — while ex­pand­ing the scope of re­search to oth­er vi­ral tar­gets.

But he’s now putting the big turn­around play in a lieu­tenant’s hands.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER